Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6942579 | 0.82 | ADRA2C (0.80) | ADRA2CMAPTALDH1A1LMNAALOX12 | |
| SCHEMBL12556830 | 0.81 | MAPT (0.58) | ADRA2CMAPTALDH1A1LMNAALOX12 | |
| SCHEMBL9915610 | 0.80 | CHRNA7 (0.50) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL7077636 | 0.80 | ADRA2C (0.77) | ADRA2CMAPTALDH1A1LMNAALOX12 | |
| SCHEMBL448110 | 0.77 | ADRA2C (1.00) | ADRA2CMAPTALDH1A1LMNAALOX12 | |
| SCHEMBL2627250 | 0.76 | ADRA2C (0.71) | ADRA2CMAPTALDH1A1LMNAALOX12 | |
| SCHEMBL14617529 | 0.76 | MAPT (0.54) | MAPTALDH1A1LMNASMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL16209754 | 0.75 | ADRA2C (0.96) | ADRA2CMAPTALDH1A1LMNAALOX12 | |
| SCHEMBL533024 | 0.74 | ADRA2C (0.68) | ADRA2CMAPTALDH1A1LMNAALOX12 | |
| SCHEMBL15289763 | 0.74 | ADRA2C (0.68) | ADRA2CMAPTALDH1A1LMNAALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9421205-B2 | FAK inhibitors | Cancer Therapeutics CRC Pty Ltd. (AU) | 2016-08-23 | — | — | US | disclosed |
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-9238644-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-19 | — | — | US | disclosed |
| US-20160009686-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-14 | — | — | US | disclosed |
| US-20150231135-A1 | FAK INHIBITORS | Cancer Therapeutics CRC Pty Ltd. (AU) | 2015-08-20 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-9012461-B2 | FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-04-21 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20140073620-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-13 | — | — | US | disclosed |
| US-20130017194-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017194-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | ADRA2C 1778/4885MAPT 2189/4885ALDH1A1 3192/4885 |
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | ADRA2C 1585/4885MAPT 2971/4885ALDH1A1 1985/4885 |
| US-20160009686-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | ADRA2C 3240/4885MAPT 3347/4885ALDH1A1 2289/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | ADRA2C 3261/4885MAPT 3456/4885ALDH1A1 2096/4885 |
| US-20140073620-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | ADRA2C 3240/4885MAPT 3347/4885ALDH1A1 2289/4885 |
| US-20150231135-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | ADRA2C 2231/4885MAPT 2447/4885ALDH1A1 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.